Read the Latest News

National Academy of Medicine to Conduct a Study on Temporomandibular Disorders

We want you to be among the first to know that because of the advocacy efforts of The TMJ Association, the National Academy of Medicine (NAM) will conduct a first-ever study on Temporomandibular Disorders (TMD).

Dentists in Distress

Fear of the dentist is practically a rite of passage in youth. Growing up, I wasn't exactly afraid of the dentist; rather, any excuse to leave school early was a powerful incentive. These days, I have a more complicated relationship with dentistry: I go to get answers and try to feel better, but I always pop a prophylactic ibuprofen or two in case my jaw protests from the oral gymnastics.

Patients in Los Angeles or New York City Needed for Clinical Study - Comparative Study of Women Considering or Currently Receiving Botox© Injections for TMJ Pain

Are you a woman with "TMJ" pain in facial muscles, who has either: a. recently had Botox© injections for your pain or b. not had Botox© for your pain but has thought about such treatment? If either is true for you, you may qualify for an observational research study centrally administered by the NYU College of Dentistry. It is funded by the National Institutes of Health (NIH). The purpose of this study is to understand potential health risks that may be caused by treating "TMJ pain" with Botox© injections.

Patients Front and Center at the 2018 TMJ Patient-Led RoundTable

It is still all too fresh in the minds of many patients. Fifty years ago, between the 1970s and 1980s, some 10,000 TMJ patients received Vitek jaw implant devices.

Funding Opportunities now available for the NIH Common Fund’s Acute to Chronic Pain Signatures program

The NIH Common Fund's Acute to Chronic Pain Signatures program aims to understand the biological characteristics underlying the transition from acute to chronic pain and what makes some people susceptible and others resilient to the development of chronic pain.

NIH GRANT OPPORTUNITIES

  • Dec 5, 2018

In an effort to promote greater understanding of Temporomandibular Disorders (TMD) and to develop safe and effective evidence-based diagnostics and treatments. The TMJ Association promotes and encourages basic and clinical research on TMD.  We invite you to view a listing of the latest National Institutes of Health (NIH) funding opportunities for scientists interested in advancing TMJ research.

Global Brain and Nervous System Disorders Research Across the Lifespan

  • Posted Date: June 19, 2018
  • Open Date: October 7, 2018
  • Expires: October 7, 2020
The mission of the National Institute of Dental and Craniofacial Research (NIDCR) is to improve dental, oral, and craniofacial health through research, research training, and the dissemination of health information; for further details, please see the NIDCR Strategic Plan 2014-2019 (https://www.nidcr.nih.gov/research/ResearchPriorities/StrategicPlan/). Through this FOA, NIDCR encourages research in orofacial pain, trigeminal neuralgia, temporomandibular joint disorder, and oral cancer pain.
 

Mechanisms, Models, Measurement, & Management in Pain Research

  • Posted Date: November 7, 2017
  • Open Date: January 6, 2018
  • Expires: May 8, 2019

Pain is a critical national health problem; it affects millions of Americans and incurs significant economic costs to society. Pain often results in disability and, even when not disabling, it has a profound effect on the quality of life.  Its deleterious effects have been demonstrated in morbidity, immune function, sleep, cognition, eating, mobility, affective state, psychosocial behaviors, and overall functional status.  In the hospitalized patient, pain may be associated with increased length of stay, longer recovery time, and poorer patient outcomes, which in turn have health care quality and cost implications.

The NIH Pain Consortium was established in 1996 to enhance pain research and promote collaboration among researchers across the many NIH ICs that have programs and activities addressing pain. Currently, the research interests of twenty-one NIH Institutes, Centers, and Offices are represented in the Consortium.  Although these combined efforts have resulted in great scientific progress, the understanding and treatment of pain remains incomplete.  In 2011, the Institute of Medicine (IOM) released its report, "Relieving Pain in America", which outlined the state of pain prevention, care, and research, and provided a blueprint to guide efforts to transform pain care in the United States.  The core recommendations of the IOM report led to development of the National Pain Strategy (NPS), which was released by HHS in 2016.  The NPS outlines the federal government’s first coordinated plan for reducing the burden of chronic pain that affects millions of Americans.  NIH is responsive to and in alignment with the NPS and the IOM report, and continues to be committed to supporting research to advance the scientific understanding of pain and the treatments available to those suffering in pain.

The NIH Pain Consortium supports research on all conditions in which pain is a prominent feature.  Of interest are diseases, such as cancer, that of themselves or their treatment may result in pain.  Many primary conditions, whether acute (such as injury), recurring (such as migraine), or chronic (such as arthritis) are significantly complicated by co-morbid pain disorders.  Some pain conditions are unassociated with other primary diagnoses.  Chronic pain is widely believed to represent a disease itself, causing long-term detrimental physiologic changes and requiring unique assessments and treatments. The areas of research detailed below and the following acute and chronic pain conditions are of special interest but do not comprise a comprehensive or complete listing of research areas relevant to this FOA.

  • Inflammatory Pain
  • Visceral pain
  • Chronic urologic pelvic pain syndromes
  • Neuropathic pain
  • Spinal cord injury pain
  • Headache
  • Musculoskeletal pain, including back pain
  • Cancer related pain (e.g. pain due to metastasis or primary disease)
  • Cardiovascular pain disorders
  • Chemotherapy-induced neuropathies and other related toxicities (e.g. aromatase inhibitor-induced arthralgias).
  • Fibromyalgia
  • Temporomandibular joint and muscle disorders
  • Pain associated with HIV/AIDS
  • Pain associated with osteoporosis
  • Pain associated with communication disorders (e.g., otitis media, tinnitus, burning mouth syndrome, dysphagia)
  • Pain at the end of life
  • Pain in older persons with multiple chronic conditions
  • Pain in people with drug and alcohol addictions
  • Pain in persons with neuromuscular conditions
  • Pain in preterm neonates exposed to multiple medical interventions and/or procedures
  • Skin disorders and pain
  • Orofacial pain

Promoting Research on Music and Health: Fundamentals and Applications

  • Posted Date: October 30, 2018
  • Open Date: January 28, 2019
  • Expires: March 1, 2019
The National Institute of Dental and Craniofacial Research (NIDCR) is interested in music research that has the potential to improve dental, oral, and craniofacial health. Areas of interest include, but are not limited to, investigations of mechanisms by which music may: i) Decrease anxiety, stress, and/or fear levels at the pre-treatment and treatment stages as well as influence levels of these during recall (memory) of the experience in pediatric and adult dental patients; including special needs populations, and ii) Modulate the experience of acute and chronic orofacial pain conditions including temporomandibular joint disorders, trigeminal neuropathies, burning mouth syndrome, oral cancer pain, dental pain, and other conditions.  The effects of music on neuroplasticity, connectivity, endogenous opioids, and differences in affective states that may exist between healthy individuals and those that suffer from chronic orofacial pain conditions are of interest. Clinical trials designed to answer specific questions about the safety, tolerability, efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, behavioral, biologic, surgical, or device interventions will only be supported by NIDCR if submitted to an NIDCR clinical trials-specific FOA https://www.nidcr.nih.gov/research/clinical-trials. Awardees will be required to comply with the  NIDCR Clinical Terms of Award for activities that involve human subjects. Investigators are encouraged to contact NIDCR program staff to discuss potential research projects prior to application submission to determine alignment of the planned studies with priorities of the Institute mission and strategic plan.
 

Research on Chronic Overlapping Pain Conditions

  • Posted Date: September 26, 2018
  • Open Date: January 16, 2019
  • Expires: January 8, 2022

The purpose of this FOA is to encourage epidemiological, clinical and translational research that will increase our understanding of the presence of multiple chronic pain conditions in subjects with pain. Recent findings suggest substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, their underlying etiologies, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with research interests bridging expertise in pain mechanisms and translational and clinical expertise to address important unresolved questions about overlapping pain conditions.

Chronic pain affects approximately 100 million Americans and exacts large economic, social and personal costs. It is a major public health challenge that needs to be addressed at multiple levels including the generation of new scientific knowledge that will enhance our understanding of these conditions. Current research efforts in chronic pain conditions have focused on single disorders or types of pain such as neuropathic and inflammatory pain. These research efforts have generated a substantial body of information advancing our discovery and understanding of the underlying mechanisms of pain onset and development, the transition from acute to chronic pain, and promising therapeutic targets for treating acute and chronic pain. Over the past twenty years sporadic reports have documented the presence of more than one chronic pain condition in subjects with pain. Studies have identified overlap between a number of chronic pain conditions, including temporomandibular joint disorder (TMD), fibromyalgia (FM), vulvodynia, functional gastrointestinal disorders such as irritable bowel syndrome (IBS), migraine, and urologic chronic pelvic pain syndromes (UCPPS). These results suggest that chronic pain conditions may not be localized conditions, but may share symptoms and mechanisms that involve a general central nervous system dysfunction as well as disorder-specific symptoms. More recent evidence is supportive of the idea that chronic pain conditions are complex disorders consistent with a biopsychosocial model of pain, and exhibit substantial overlap. Therefore, this may be an opportune time to encourage research efforts that focus, not on single pain conditions, but on subjects with multiple chronic pain disorders.

Analytical and/or Clinical Validation of a Candidate Biomarker for Pain

(R61/R33) https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-046.html 

  • Posted Date: September 19, 2018
  • Open Date: October 27, 2018
  • Expires: March 13, 2020

The purpose of this Funding Opportunity Announcement (FOA) is to promote the validation of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.  Specifically, the focus of this FOA is on advanced analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints using retrospective and/or prospective methods. It is assumed that: 1) a candidate biomarker has already been identified, 2) assay technology has already been developed, and 3) a working hypothesis regarding Context of Use is in place. Research supported by this FOA will ultimately demonstrate that biomarker or endpoint change is reliably correlated with variables such as clinical outcome, pathophysiologic subsets of pain, therapeutic target engagement or response to a pain therapeutic; in addition, biomarker response will demonstrate specificity to the pain condition or therapeutic as demonstrated at multiple clinical sites. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers, biomarker signatures and endpoints of pain to application in clinical trials (Phase II clinical trials and beyond) and in the spectrum of clinical practice. 

Discover and Validation of Novel Targets for Safe and Effective Pain Treatment

(R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-043.html 

(R21) https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-042.html 

  • Posted Date: September 19, 2018
  • Open Date: October 27, 2018
  • Expires: November 13, 2019

The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics.  Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery.

This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.

Discovery of Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)

(R61/R33) https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-041.html

  • Posted Date: August 2, 2018
  • Open Date: October 27, 2018
  • Expires: March 13, 2020

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.  Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints. Although research supported by this FOA can include animal studies, it must also include preliminary human validation research using carefully standardized human samples or human clinical studies. The goal of this initiative is to deliver candidate biomarkers, biomarker signatures, and/or endpoints that are ready for advanced clinical and analytical validation research.

Clinical Validation of Candidate Biomarkers for Neurological Diseases

  • Posted Date: February 14, 2018
  • Open Date: March 17, 2018
  • Expires: February, 14, 2019; July 18, 2019; February 14, 2020; and July 20, 2020
The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of diseases that fall within the mission of NINDS to application in clinical trials and practice (Phase II clinical trials and beyond).
 

Factors Underlying Differences in Female and Male Presentation for Dental, Oral, and Craniofacial Diseases and Conditions

(R01): http://grants.nih.gov/grants/guide/pa-files/PA-16-295.html

(R21): http://grants.nih.gov/grants/guide/pa-files/PA-16-296.html

  • Posted Date: May 27, 2016
  • Open Date: September 16, 2016
  • Expires: September 8, 2019

The purpose of this funding opportunity announcement (FOA) is to encourage research on mechanisms underlying the manifestations of sex-based differences in Dental, Oral, and Craniofacial (DOC)-related diseases and conditions.  Specifically, this initiative encourages studies aimed at understanding immune reactivity, genetic variation, environmental triggers, aging, and hormonal changes as they affect sex-based differences in DOC-related diseases and conditions including, but not limited to, Sjögren’s Syndrome (SS), orofacial pain, temporomandibular joint (TMJ) disorder (TMD), salivary gland tumors, and human papillomavirus (HPV)-associated oropharyngeal cancers. 

NIDCR Small Research Grants for Secondary Analysis of FaceBase Data (R03)

(R03): http://grants.nih.gov/grants/guide/pa-files/PAR-16-362.html

  • Posted Date: July 11, 2016
  • Open Date: September 16, 2016
  • Expires: September 8, 2019

The FaceBase Consortium is developing a variety of comprehensive datasets on craniofacial development that are available to the wider scientific community at www.facebase.org. This funding opportunity announcement (FOA) will support meritorious research projects that conduct secondary data analyses of these FaceBase datasets relevant to craniofacial development, human craniofacial conditions or traits, and animal models of those craniofacial conditions.  Informatics projects that integrate data from multiple FaceBase datasets are especially encouraged.

NIDCR Small Research Grants for Data Analysis and Statistical Methodology Applied to Genome-wide Data

(R03): https://grants.nih.gov/grants/guide/pa-files/PAR-16-070.html

  • Posted Date: January 8, 2016
  • Open Date: January 16, 2016
  • Expires: May 8, 2019

The purpose of this FOA is to provide support for meritorious research projects that involve statistical analysis of existing genome-wide data (e.g. genome-wide SNP genotyping; DNA sequencing; transcriptomic, metagenomic, epigenomic, or gene expression data) relevant to human dental, oral, or craniofacial conditions or traits. Development of statistical methodology appropriate for analyzing genome-wide data, relevant to human dental, oral, or craniofacial conditions or traits, may also be proposed.

Tailoring Dental Treatment for Individuals with Systemic Diseases that Compromise Oral Health

(R01): http://grants.nih.gov/grants/guide/pa-files/PAR-16-154.html

(R21): http://grants.nih.gov/grants/guide/pa-files/PAR-16-153.html

  • Posted Date: March 25, 2016
  • Open Date: May 16, 2016
  • Expires: May 8, 2019

This Funding Opportunity Announcement encourages research to address gaps in our knowledge of how best to treat oral diseases of patients with systemic diseases or conditions known to compromise oral health, to identify factors predictive of treatment outcomes within patient groups, and to generate evidence for more precise dental treatment guidelines tailored to patient needs. It is expected that research applications will propose studies utilizing established cohorts of individuals with the disease of interest.

Personalized Strategies to Manage Symptoms of Chronic Illness

(R15): http://grants.nih.gov/grants/guide/pa-files/PA-16-006.html

(R01): http://grants.nih.gov/grants/guide/pa-files/PA-16-007.html

(R21): http://grants.nih.gov/grants/guide/pa-files/PA-16-008.html

  • Posted Date: October 16, 2015
  • Open Date: January 25, 2016
  • Expires: January 8, 2019

The purpose of this initiative is to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness through a) increasing knowledge of the biological mechanisms of symptoms and b) promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms. 

Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing

(R01): http://grants.nih.gov/grants/guide/pa-files/PA-15-347.html

  • Posted Date: September 17, 2015
  • Open Date: January 5, 2016
  • Expires: January 8, 2019

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that elucidate the mechanisms and/or behavioral outcomes of multisensory processing, the integration or processing of at least two distinct types of sensory input as defined by distinct receptor-type transduction, neural pathways and cognate perceptual quality.  Specifically, multiple sensory inputs may include the major traditional modalities of hearing, vision, taste, smell, balance, and touch.  Additional submodalities of body senses include but are not restricted to thermosensation, body position and proprioception, pain, itch, and general visceral sensation.  This FOA encourages research grant applications investigating multisensory processing in perception or other behavioral and social outcomes and/or the mechanisms underlying multisensory processing in the context of the described specific areas of research interests from the participating NIH Institutes, Centers, and Offices (ICOs).  The FOA is intended to encourage basic, behavioral, and/or clinical research projects examining the interactions between other neural systems, such as cognitive, affective, or motor processes, and multiple sensory modalities.  Multisensory research applications that do not align with the specific areas of research interests described below by the participating NIH ICOs should be submitted to the parent R01 FOA, PA-13-302.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System

(UH2/UH3): https://grants.nih.gov/grants/guide/pa-files/PAR-17-205.html

  • Posted Date: December 21, 2017
  • Open Date: January 7, 2018
  • Expires: May 8, 2020

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

NIDCR is interested in neurotherapeutics development for painful disorders of the orofacial region including temporomandibular joint disorder, trigeminal neuropathies, burning mouth syndrome, and other conditions.  Recent advances in genomics and phenotyping of subjects with orofacial pain conditions have expanded the scope of potential targets to treat these conditions. Receptor systems, ion channels, and pro- and anti-inflammatory molecules have been implicated in chronic pain. NIDCR is interested in supporting research that will lead to highly efficacious and specific pharmacological treatments of subjects with orofacial pain disorders.

Investigators are encouraged to contact NIDCR program staff to discuss potential research projects prior to application submission to determine alignment of the planned studies with priorities of the Institute mission and strategic plan.

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.     - See more at: http://grants.nih.gov/grants/guide/pa-files/PAR-14-293.html#sthash.mGoDkIgW.dpuf
The purpose of this Funding Opportunity Announcement (FOA)is to encourage research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which we do not have a strong understanding of the genetics/genomics of the disease or disorder. Applicable areas of investigation include identification of promising areas of the genome, and characterization and elucidation of the function(s) of genetic variants that affect disease risk in humans. The ultimate goal of these studies will be to drive development of effective diagnostic, therapeutic, and preventive approaches. - See more at: http://grants.nih.gov/grants/guide/pa-files/PA-14-347.html#sthash.viviyVB9.dpuf

Population Health Interventions: Integrating Individual and Group Level Evidence

(R01): https://grants.nih.gov/grants/guide/pa-files/PA-18-356.html

  • Posted Date: November 21, 2017
  • Open Date: January 5, 2018
  • Expires: May 8, 2019

To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.

Family-Centered Self-Management of Chronic Conditions

(R21): https://grants.nih.gov/grants/guide/pa-files/PA-18-380.html

(R01):https://grants.nih.gov/grants/guide/pa-files/PA-18-383.html

  • Posted Date: November 21, 2017
  • Open Date: January 16, 2018 / January 5, 2018
  • Expires: January 8, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of family-centered self-management (FCSM) in chronic conditions.

mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management

(R01): https://grants.nih.gov/grants/guide/pa-files/PA-18-386.html

(R21): https://grants.nih.gov/grants/guide/pa-files/PA-18-389.html

  • Posted Date: November 21, 2017
  • Open Date: January 5, 2018
  • Expires: January 8, 2021

The purpose of this initiative is to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations. 

The Biomarkers Consortium

The Biomarkers Consortium, a research partnership managed by the Foundation for the National Institutes of Health, is soliciting concepts for biomarker projects. Researchers are encouraged to submit project concepts online at http://www.biomarkersconsortium.org. If a concept is approved for development by the consortium, the Foundation for NIH will seek funds to support the project.

The consortium is a large-scale, public-private research partnership formed in 2006 to identify and qualify biomarkers. It encourages participation by academia, government, industry, patient advocacy groups and other non-profit organizations. In addition to the Foundation for NIH, founding members of the consortium include the NIH, the Food and Drug Administration and the Pharmaceutical Research and Manufacturers of America.

Information about the Foundation for NIH is available at http://www.fnih.org.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System

  • Posted Date: December 21, 2017
  • Open Date: January 7, 2018
  • Expires: May 8, 2020

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program. 

NIDCR is interested in neurotherapeutics development for painful disorders of the orofacial region including temporomandibular joint disorder, trigeminal neuropathies, burning mouth syndrome, and other conditions.  Recent advances in genomics and phenotyping of subjects with orofacial pain conditions have expanded the scope of potential targets to treat these conditions. Receptor systems, ion channels, and pro- and anti-inflammatory molecules have been implicated in chronic pain. NIDCR is interested in supporting research that will lead to highly efficacious and specific pharmacological treatments of subjects with orofacial pain disorders.

Investigators are encouraged to contact NIDCR program staff to discuss potential research projects prior to application submission to determine alignment of the planned studies with priorities of the Institute mission and strategic plan.

This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf
This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf
This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf